Company: ARVN
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001655759-25-000075
Chunk: 36

Company: ARVINAS, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 36
---
4, upon approval by the board of directors, Mr. Saik was granted an Option and RSUs as an inducement material to entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Other Management Changes

Effective March 18, 2024, the board of directors appointed Noah Berkowitz, M.D., Ph.D., as our Chief Medical Officer. In connection with the commencement of his employment, in addition to the base salary, bonus as a percentage of base salary and any termination payments Dr. Berkowitz may be entitled to in the future that are outlined in the employment agreement entered into with Dr. Berkowitz, on March 18, 2024, upon approval by the board of directors, Dr. Berkowitz was granted an Option and RSUs as an inducement material to entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). These inducement grants granted to Dr. Berkowitz were also intended to capture any value that Dr. Berkowitz may have left at his prior employer.

Effective June 17, 2024, the board of directors appointed Ian Taylor, Ph.D., as our President of R&D, a role previously held by Dr. Houston. Prior to this, Dr. Taylor served as our Chief Scientific Officer. In connection with this new role, though Dr. Taylor remained an executive officer, his base salary was adjusted downward.

Also effective June 17, 2024, the board of directors appointed Angela Cacace, Ph.D., our then Senior Vice President, Neuroscience and Platform Biology, as our Chief Scientific Officer, a role previously held by Dr. Taylor. In connection with this new role, Dr. Cacace’s base salary and bonus as a percentage of base salary were increased and, on June 17, 2024, following approval by the board of directors, Dr. Cacace was granted additional equity awards in the form of an Option and RSUs.

Key Compensation Decisions and Action Regarding 2024 Executive Compensation

Our board of directors and compensation committee made several key compensation decisions regarding the 2024 compensation of our executives taking into account our compensation philosophy and objectives, the needs and performance of our company, individual performance, and other factors such as market data and industry best practices.

• Base Salary Adjustments. In February 2024, the board of directors, upon recommendation by the compensation committee, reviewed and approved the base salary of our Chief Executive Officer and the compensation committee